返回 
加入收藏
参芍胶囊治疗冠心病不稳定型心绞痛的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 参芍胶囊治疗冠心病不稳定型心绞痛的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察参芍胶囊治疗冠心病不稳定型心绞痛（UA）患者的临床疗效及对心率、血压、心肌耗氧量及血清 hs-CRP、MMP-9的影响。方法：选择2014年5月－2016年5月我院收治的冠心病UA患者77 例，按随机数字表法分为观察组（39例）和对照组（38例）。对照组患者给予常规对症治疗； 观察组患者在对照组基础上加服参芍胶囊 1.2 g，tid。两组患者均治疗4周。观察两组患者治疗前后心率、血压、心肌耗氧量及血清 hs-CRP、MMP-9 水平，比较两组患者硝酸甘油停减率和心电图ST段疗效。结果：两组患者治疗前心率、血压、心肌耗氧量及血清 hs-CRP、MMP-9水平比较，差异无统计学意义（P＞0.05）；治疗后，两组患者上述指标水平均显著降低，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）。观察组患者硝酸甘油停减率为82.1％，心电图ST段有效率为87.2％，均优于对照组的63.2％、78.9％，差异有统计学意义（P＜0.05）。结论：参芍胶囊治疗冠心病UA疗效显著，能明显降低患者心率、血压、心肌氧耗量及血清 hs-CRP、MMP-9 水平。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy of Shenshao capsules in the treatment of unstable angina （UA） of coronary heart disease， and its effects on heart rate， blood pressure， myocardial consumption of oxygen （MCO）， serum levels of hs-CRP and MMP-9. METHODS： 77 UA patients with coronary heart disease selected from our hospital during May 2014-May 2016 were divided into observation group （39 cases） and control group （38 cases） according to random number tablet. Control group received rountine treatment. Observation group was additionally given Shenshao capsule 1.2 g， tid， on the basis of control group. Both groups were treated for 4 weeks. The heart rate， blood pressure， myocardial oxygen consumption， serum levels of hs-CRP and MMP-9 in 2 groups were observed before and after treatment； stopping and reduced rate of nitroglycerin， and therapeutic efficacy of ECG ST segment were compared between 2 groups. RESULTS： There was no statistical significance in heart rate， blood pressure， myocardial oxygen consumption， serum levels of hs-CRP and MMP-9 between 2 groups before treatment （P＞0.05）. After treatment， above indexes of 2 groups were decreased significantly， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. The stopping and reduced rate of nitroglycerin， total response rate of ECG ST segment were 82.1％， 87.2％ in observation group， which were better than 63.2％，78.9％ in control group， with statistical significance （P＜0.05）. CONCLUSIONS： Shenshao capsules is effective for coronary heart disease UA， and can effectively reduce heart rate， blood pressure， myocardial oxygen consumption， serum levels of hs-CRP and MMP-9. |
| 期刊： | 2017年第28卷第11期 |
| 作者： | 刘羿妍，李浦媛，李晟琰，李连茂 |
| AUTHORS： | LIU Yiyan，LI Puyuan，LI Shengyan，LI Lianmao |
| 关键字： | 参芍胶囊；冠心病；不稳定型心绞痛 |
| KEYWORDS： | Shenshao capsules； Coronary heart disease； Unstable angina |
| 阅读数： | 321 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
